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To assess the relation between urinary endogenous sex steroid levels and the risk of postmenopausal breast cancer, a nested case–
cohort study was conducted within a large cohort (the DOM cohort) in the Netherlands (n¼9349). Until the end of follow-up (1
January 1996), 397 postmenopausal breast cancer cases were identified and a subcohort of 424 women was then taken from all
eligible women. Women using hormones were excluded, leaving 364 breast cancer cases and 382 women in the subcohort for the
analyses. Concentrations of oestrone, oestradiol, testosterone, 5a-androstane-3a,1 7 b-diol and creatinine were measured in first
morning urine samples, which had been stored since enrolment at  201C. A Cox proportional Hazards model was used, with
Barlow’s adjustment for case–cohort sampling, to estimate breast cancer risk in quartiles of each of the, creatinine corrected,
hormone levels, the lowest quartile being the reference group. Women with higher levels of all four of the hormones were at
increased risk for postmenopausal breast cancer (highest vs lowest quartile: incidence rate ratio for oestrone (IRRoestrone¼2.5,
95% CI: 1.6–3.8; IRRoestradiol¼1.5, 95% CI: 1.0–2.3; IRRtestosterone¼1.6, 95% CI: 1.0–2.4; IRR5a-androstane-3a,1 7 b-diol¼1.7, 95%
CI: 1.1–2.7). In conclusion, women with higher excretion levels of both oestrogens and androgens have an increased risk of breast
cancer.
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Established risk factors for breast cancer, such as early age at
menarche, late age at menopause, late age at first full-term
pregnancy or nulliparity, indicate that endogenous sex hormones
play an important role in breast cancer aetiology (Bernstein and
Ross, 1993).
For almost 30 years now, several case–control and cohort
studies addressed this topic. Recently, a pooled analysis of nine
prospective studies, including 663 breast cancer cases and 1765
controls, showed that postmenopausal women in the highest
quintiles of oestrone-, oestradiol- and testosterone concentrations
in blood had a statistically significant two-fold increased risk of
breast cancer (The Endogenous Hormones and Breast Cancer
Collaborative Group, 2002). However, this pooled analysis was
based on nine relatively small prospective studies, which in
themselves did not show consistent results, probably because of
lack of power (Garland et al, 1992; Helzlsouer et al, 1994; Toniolo
et al, 1995; Berrino et al, 1996; Dorgan et al, 1996; Thomas et al,
1997; Hankinson et al, 1998; Cauley et al, 1999; Kabuto et al, 2000).
And in the five largest of these studies, the median time to
diagnosis was less than 3 years, while the other four had much
longer follow-up (The Endogenous Hormones and Breast Cancer
Collaborative Group, 2002).
To further evaluate the relation between urinary endogenous sex
steroids (i.e. oestrone, oestradiol, testosterone and 5a-androstane-
3a,1 7 b-diol) and the risk of postmenopausal breast cancer, we
conducted a nested case–cohort study in a large population-based
prospective cohort study in the Netherlands.
METHODS
Subjects
All women born between 1911 and 1945 living in Utrecht and
surroundings were invited to participate in a large population-
based screening programme for early detection of breast cancer
(the DOM-cohort) between 1975 and 1986 (de Waard et al, 1984).
All participants were asked to fill in a lifestyle questionnaire
containing questions regarding breast cancer-risk factors, medical
history, exogenous hormone use and menopausal status. Also,
anthropometric measurements (e.g. height, weight) were taken and
women were asked to donate a first morning urine sample on the
day of their examination. Urine samples were then stored at  201C
in 250ml plastic polypropylene jars, without preserving agents,
until analysis. A total of 27718 women participated in this cohort.
Women who were naturally postmenopausal at recruitment
(defined as no menstrual period for at least 12 months, after
spontaneous cessation of their menses) and who had no history of
breast cancer were eligible for the present study (n¼9349). All
women were followed until 1st January 1996 for the occurrence of
breast cancer through their general practitioners and, from 1986
onwards, through linkage with the regional cancer registry. A
nested case–cohort study was designed to study the relation
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breast cancer. Until the end of follow-up, 397 breast cancer cases
were identified and a random sample of 424 women (the
subcohort) was taken from all eligible women. A urine sample
could not be found for three cases and three women from the
subcohort. Women using hormone replacement therapy or oral
contraceptives at the time of urine sampling were excluded (30
cases and 38 women from the subcohort). Urine samples were sent
to the International Agency for Research on Cancer (IARC), Lyon,
France, for hormonal measurements. One sample was lost during
the analyses and was excluded, leaving 364 cases and a subcohort
of 382 women for the analyses.
Hormone measurement
Urine samples were analysed at the IARC in Lyon, France.
Laboratory technicians were blinded as to the disease status of the
samples. Equal numbers of samples taken from the case group and
from the subcohort were analysed together within batches of 22
urine samples. The hormone metabolites, oestrone (E1), oestradiol
(E2), testosterone (TST) and 5a-androstane-3a, and 17b-diol (3aD)
were measured by radioimmunoassay (RIA) after enzymatic
hydrolysis, solid phase extraction and high-performance liquid
chromatography (HPLC) purification of the urine samples. Results
were expressed in nanogram analyte per litre. The method used in
this study has been described in detail elsewhere (Rinaldi et al,
2003). Intra- and interassay coefficients of variation were 8.7 and
17.2% for E1, 12.2 and 14.8% for E2, 8.3 and 15.3% for TST and 9.0
and 11.4% for 3aD. Reproducibility of these assays in urine was
tested in a random sample of 45 postmenopausal women from the
DOM cohort, who delivered urine samples at three different
examinations of breast cancer screening and who did not use
exogenous hormones. The average time interval between the first
and second urine collection was 1.1 years (0.9–4.4 years) and
between the second and the third collection was 4.0 years (1.3–7.7
years). Intraclass correlation coefficients for sample replicates were
above 0.93 for all four hormone metabolites, indicating good
reproducibility from a laboratory error perspective. The intraclass
correlation coefficients over time were 0.59 for E1, 0.62 for E2, 0.85
for TST and 0.55 for 3aD, indicating reasonable stability of women’s
urinary hormone levels over several years (Rinaldi et al,2 0 0 3 ) .
Creatinine was measured in each sample by kinetic Jaffe ´ reaction
(Hitachi 717, Roche, Central laboratory for Biochemistry, Ho ˆpital
de l’Antiquaille, Lyon, France).
Data analyses
To correct for between-subject variability in urine dilution, in each
sample the hormone concentration (expressed in ng/l) was divided
by the creatinine concentration (expressed in mg/l). All analyses
included creatinine-adjusted hormone levels.
Concentrations of all four hormone-metabolites were logarith-
mically transformed to produce approximately normal distribu-
tions. Geometric mean values and their 95% confidence intervals
were then calculated in cases and in the subcohort.
Women were classified into quartiles of concentrations of E1,
E2, TST and 3aD, based on the distribution of the creatinine-
corrected hormone levels in the subcohort. Women with hormone
levels below the detection limit (E1: n¼5; E2: n¼4; TST: n¼1;
3aD: n¼0) were included in the lowest quartile. Incidence rate
ratios (IRR) were calculated in each quartile compared to the first,
using a Cox Proportional Hazards Model with Barlow’s weighting
method (Barlow et al, 1999). Family history (yes/no), defined as at
least a mother or one sister diagnosed with breast cancer, smoking
(ever, never), parity (nulliparous/parous), time since menopause,
age at menopause, age at first full-term pregnancy (no children,
o25, 25–29, 429) and socioeconomic status (SES), based on type
of health insurance (low: public health insurance; intermediate:
civil servants plan; high: private insurance) were evaluated for
confounding. If the IRR changed by 10% or more when one of
these variables was included, the variable was then included in the
final model to adjust the IRR. Body mass index (BMI) is often
considered to be in the aetiological pathway, because in
postmenopausal women oestrogens are mainly formed through
the aromatisation of androgens in fatty tissue. Therefore, IRRs
with and without adjustment for BMI are presented. Elevated
breast cancer risks found for androgens may be caused by
aromatisation of androgens into oestrogens. To check whether
androgens have an independent effect on breast cancer risk, we
calculated standardised values for each of the four hormone
metabolites. We then added the standardised values of the two
oestrogens and classified women according to high or low
oestrogen levels along the median (cutoff:  0.2672). The same
procedure was followed for the androgens (cutoff:  0.3883).
Subsequently, a new variable was calculated, clustering women
into four categories, according to their combined level of exposure
to oestrogens and androgens, that is, both low, low in oestrogens
and high in androgens and vice versa, or high in both oestrogens
and androgens. IRRs were calculated for each category compared
to women who were low for both (standardised) oestrogen- and
androgen levels.
To evaluate the effect of latent disease at urine collection on
breast cancer risk, we studied the association between levels of
hormone concentrations and the risk for breast cancer for those
women who were free of breast cancer for at least 2 years after
urine sample collection. To evaluate the influence of the time
interval between urine collection and the diagnosis, analyses were
done separately for women who developed breast cancer within the
first 9 years of follow-up and after 10 years. Linear trends were
tested by including quartile scores 1, 2, 3 and 4 as a continuous
variable in the model.
Cox Proportional Hazards models were performed using the SAS
macro described by Barlow et al (1999). For all other statistical
analyses, the Statistical Package for Social Sciences (SPSS) was used.
RESULTS
The median follow-up in the subcohort was 19 years (range 0–21
years). Compared to the subcohort, women with breast cancer
more often reported a positive family history of breast cancer and
were slightly heavier (Table 1). Case women showed higher
geometric mean levels of all four hormone-metabolites at
enrolment, although none of these differences were statistically
significant (Table 2).
Table 3 shows the IRRs for each quartile of levels of E1, E2, TST
and 3aD adjusted for family history of breast cancer. Compared to
the lowest quartiles of oestrogens (E1 and E2), women with higher
levels of these metabolites were found to be at higher risk of
developing breast cancer (highest vs lowest quartile: IRRE1¼2.5,
95% CI: 1.6–3.8; IRRE2¼1.5, 95% CI: 1.0–2.3). Tests for trend
were statistically significant for both oestrogens.
Also, women with higher levels of both testosterone and 3aD
had an increased risk of breast cancer (highest vs lowest quartile:
IRRTST¼1.6, 95% CI: 1.0–2.4; IRR3aD¼1.7, 95% CI: 1.1–2.7), with
statistically significant tests for trend. Analysis of hormone levels
unadjusted for creatinine, showed similar results, but relative risks
were slightly smaller and not all statistically significant anymore.
Additional adjustment for BMI did not change the risks
associated with any of the hormone metabolites (Table 3).
Excluding from the analysis women with a diagnosis within the
first 2 years after urine collection did not alter the results (data not
shown).
Table 4 shows that all four hormone metabolites were correlated
with each other. We tried to disentangle the effects of oestrogens
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shows that, independent from the level of total oestrogen, women
with high levels of androgens are at increased risk for breast cancer
(IRR¼1.4; 95% CI: 0.9–2.3). If women have high levels of both
oestrogens and androgens, the risk of breast cancer is slightly
higher compared to the risk of oestrogens and androgens
separately (IRR¼1.7; 95% CI: 1.1–2.4), although this difference
was not statistically significant.
Table 6 shows the risk of breast cancer in quartiles of each of the
four hormones stratified according to the time interval between
urine collection and the diagnosis of breast cancer cases. Especially
in the highest quartile of each of the four hormones, the risks seem
to be somewhat diluted if the periods between urine collection and
the diagnosis of breast cancer was over 9 years. Except for
oestrone, tests for trend were no longer statistically significant. If
the period between urine collection and the diagnosis of breast
cancer was less than 10 years, women with elevated hormone levels
showed increased risk. Tests for trend were statistically significant
for all four hormone metabolites (Table 6).
DISCUSSION
The present prospective study shows that postmenopausal women
with higher excretion levels of oestrogens as well as androgens
have an increased risk of breast cancer.
Certain aspects of the study need to be considered. The number
of women who developed breast cancer was fairly large (n¼364)
and follow-up was long (median time to diagnosis¼9.8 years).
The largest prospective study so far published included 156 cases
and a median time to diagnosis of 2.6 years (Hankinson et al,
1998), while the study with the longest follow-up (median¼12
years) included 29 breast cancer cases and 58 controls (Helzlsouer
et al, 1994; The Endogenous Hormones and Breast Cancer
Collaborative Group, 2002). A possible disadvantage of a short
follow-up is that breast tumours occurring during follow-up may
have already been present at the time of enrolment in the study.
Recent evidence shows that, apart from possible promotion of
breast cancer through the stimulation of cell proliferation,
circulating oestrogens might also act in the initiation. This
initiation might occur either because oestrogens increase the
mitotic activity and therefore the probability that DNA damage is
not repaired and converted into DNA mutations (Pike et al, 1993),
or through the formation of oxidative metabolites, which can
directly form DNA adducts (Yager, 2000). Possible effects on
initiation of the tumour cannot be picked up in studies with short
follow-up. Our study shows that the risk of breast cancer was
clearly increased in women who developed breast cancer in the
first 9 years of follow-up. These results suggest that endogenous
sex steroids have their effect predominantly on the promotion of
breast tumours, which is in line with several other observations,
such as the rather rapid effect of menopause on breast cancer risk
(Pike et al, 1993). However, we cannot completely exclude the
possibility that there may be an early stage effect as well, since
increased risks were also observed for women diagnosed more
than 9 years after urine collection. This would be in line with the
long-lasting effects of, for instance, age at menarche (Baanders and
de Waard, 1992; Peeters et al, 1995).
Table 1 Characteristics of the study population
Subcohort
(n=382)
Breast cancer cases
(n=364)
Age at intake (median, range) 58 (43–66) 58 (41–65)
Age at menopause (median, range) 50 (37–60) 50 (36–60)
Years since menopause (median, range) 7 (0–25) 7 (0–26)
Age at menarche (median, range) 13.3 (10.2–18.0) 13.0 (10.5–18.0)
Nulliparous 81 (21.2%) 65 (17.9%)
If parous: number of children (median, ranged) 3 (1–9) 2 (1–9)
Age at first full-term pregnancy (median, range) 27 (18–42) 27 (16–41)
Positive family history of breast cancer
a 28 (7.4%) 54 (15.2%)
Ever smoking 99 (25.9%) 91 (25.6%)
Body mass index (kgm
 2) (mean, s.d.) 26.1 (4.2) 26.8 (4.1)
Height (cm) (mean, s.d.) 162.1 (6.1) 162.5 (6.2)
Weight (kg) (mean, s.d.) 68.4 (11.1) 70.8 (11.6)
SES
Low 263 (68.8%) 525 (69.2%)
Medium 41 (10.7%) 43 (11.8%)
High 78 (20.4%) 69 (19.0%)
aAt least one first-degree relative with breast cancer.
Percentage of missing values varied from 0 to 1.3% per variable, except for age at menarche, which was only asked in a
subgroup (147 breast cancer cases and 198 in subcohort).
Table 2 Geometric means and 95% confidence intervals for levels of oestrone, oestradiol, testosterone
and 5a-androstane-3a,1 7 b-diol in breast cancer cases and in the subcohort
Subcohort Breast cancer cases
Geometric
mean 95% CI
Geometric
mean 95% CI
Oestrone (ngmg
 1 creatinine) 1.76 0.46–6.68 1.98 0.56–6.95
Oestradiol (ngmg
 1 creatinine) 0.53 0.13–2.12 0.58 0.16–2.15
Testosterone (ngmg
 1 creatinine) 2.64 0.64–10.84 2.94 0.75–11.45
5a-androstane-3a,1 7 b-diol (ngmg
 1 creatinine) 21.87 6.31–75.74 24.16 7.79–74.91
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hormone binding globulin and albumin, and it has been suggested
that only unbound sex steroids could have their effects in breast
epithelial cells (Bernstein and Ross, 1993; Pike et al, 1993). We
classified women according to their hormone levels in urine.
Measurements in urine reflect metabolised amounts of hormones,
but it is not clear how these levels relate to biologically active levels
in breast tissue. Therefore, using urine levels to classify women’s
exposure to endogenous sex steroids could lead to misclassifica-
tion. However, because disease had not yet occurred at the time of
urine collection, misclassification is likely to have been nondiffer-
ential and therefore to have led to an underestimation of the risk.
The risks for breast cancer associated with oestrogen levels
found in the present study are in concordance with results from
Table 3 Breast cancer risks for quartiles of oestrone, oestradiol, testosterone and 5a-androstane-3a,1 7 b-diol
Women in
subcohort
(n=382)
Breast cancer
cases
(n=364) IRR
a 95% CI IRR
b 95% CI
Oestrone
a
0.06–1.19ngmg
 1 95 57 1.0 F 1.0 F
1.19–1.77ngmg
 1 95 95 1.9 1.2–3.0 1.9 1.2–3.0
1.78–2.50ngmg
 1 95 79 1.2 0.8–2.0 1.2 0.8–2.0
42.50ngmg
 1 95 132 2.5 1.6–3.8 2.4 1.5–3.8
Ptrend 0.001 0.002
Oestradiol
0.08–0.34ngmg
 1 95 77 1.0 F 1.0 F
0.34–0.49ngmg
 1 96 79 1.1 0.7–1.7 1.1 0.7–1.7
0.49–0.77ngmg
 1 96 101 1.4 0.9–2.1 1.4 0.9–2.1
40.77ngmg
 1 95 107 1.5 1.0–2.3 1.5 1.0–2.3
Ptrend 0.03 0.03
Testosterone
0.03–1.85ngmg
 1 96 80 1.0 F 1.0 F
1.86–2.71ngmg
 1 95 78 1.1 0.7–1.7 1.1 0.7–1.7
2.72–4.16ngmg
 1 96 97 1.5 0.9–2.3 1.5 1.0–2.3
44.16ngmg
 1 95 109 1.6 1.0–2.4 1.6 1.0–2.4
Ptrend 0.02 0.02
5a-androstane-3a,1 7 b-diol
c
0.85–15.93ngmg
 1 95 62 1.0 F 1.0 F
15.94–23.67ngmg
 1 96 103 1.7 1.1–2.7 1.7 1.1–2.7
23.68–33.65ngmg
 1 96 101 1.7 1.1–2.6 1.7 1.1–2.6
433.65ngmg
 1 95 97 1.7 1.1–2.7 1.8 1.1–2.8
Ptrend 0.03 0.03
aAdjusted for family history of breast cancer (yes/no).
bAdditional adjustment for BMI.
cMeasurements for oestrone were missing in one case and two women from the
subcohort. Measurements for 5a-androstane-3a,1 7 b-diol were missing for one case. IRR, incidence rate ratio.
Table 4 Correlation coefficients for the correlation between the concentrations of each of the four
hormones
Oestrone Oestradiol Testosterone 5a-androstane-3a,1 7 b-diol
Oestrone 1.0 0.93** 0.10* 0.08*
Oestradiol 2 1.0 0.13** 0.11**
Testosterone 1.0 0.53**
5a-androstane-3a,1 7 b-diol 1.0
*Po0.05; **Po0.01.
Table 5 Risk of breast cancer for high levels of oestrogens and androgens
Levels of
oestrogen/androgen
a
Women in subcohort
(n=380)
Breast cancer cases
(n=362) IRR 95% CI
Low/low 143 113 1.0 F
Low/high 63 53 1.4 0.9–2.3
High/low 60 58 1.4 0.9–2.3
High/high 114 138 1.7 1.1–2.4
aBased on the median of the standardised values of each of the hormone levels. IRR, incidence rate ratio.
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been published on oestrogen levels in either serum or urine
(Garland et al, 1992; Helzlsouer et al, 1994; Toniolo et al, 1995;
Berrino et al, 1996; Dorgan et al, 1996; Key et al, 1996; Thomas
et al, 1997; Hankinson et al, 1998; Cauley et al, 1999; Kabuto et al,
2000). Eight of these studies showed a positive association of
oestradiol with breast cancer risk in postmenopausal women
(Toniolo et al, 1995; Berrino et al, 1996; Dorgan et al, 1996; Key
et al, 1996; Thomas et al, 1997; Hankinson et al, 1998; Cauley et al,
1999; Kabuto et al, 2000), although statistically significant in only
four (Toniolo et al, 1995; Thomas et al, 1997; Hankinson et al,
1998; Cauley et al, 1999). Most of the prospective studies included
a small number of cases (24–156 cases per study).
Also, for testosterone, we observed an increased risk for breast
cancer. Prospective studies showed an increased risk for breast
cancer for the aromatisable androgens (testosterone and andros-
tenedione) in most cases (Berrino et al, 1996; Dorgan et al, 1996;
Thomas et al, 1997; Zeleniuch-Jacquotte et al, 1997; Cauley et al,
1999), but not statistically significant in all (Helzlsouer et al, 1994;
Hankinson et al, 1998). In one study, no increased risk was
observed (Garland et al, 1992).
The estimates for breast cancer risk in the highest quartiles of
oestrone, oestradiol and testosterone found in this study were
lower than those found in studies that used blood (Toniolo et al,
1995; Berrino et al, 1996; Dorgan et al, 1996; Thomas et al, 1997;
Hankinson et al, 1998; Cauley et al, 1999; Kabuto et al, 2000), but
quite similar to the only other prospective study that used urine
samples (Key et al, 1996). A recently pooled analysis of nine
prospective studies on serum levels found a two-fold increased risk
in the highest quintiles of oestrone, oestradiol and testosterone
(The Endogenous Hormones and Breast Cancer Collaborative
Group, 2002).
For elevated levels of the nonaromatisable androgen 3aD, we
also found an increased risk for breast cancer. To our knowledge
no prospective studies have examined the risk of breast cancer for
circulating androgens that cannot be aromatised into oestrogens,
such as dihydrotestosterone or its metabolites. However, one
case–control study also showed an increased risk in postmeno-
pausal women who had elevated levels of serum dihydrotestoster-
one (highest vs lowest quartile: OR¼2.0, 95% CI: 0.8–5.0) and
urinary androstanediol (highest vs lowest quartile: OR¼3.4, 95%
CI: 1.4–8.7) (Secreto et al, 1991). In addition, we found that
women with high levels of androgens but low levels of oestrogens
had an increased risk. These results suggest that, apart from
conversion into oestrogens, androgens may also have a direct
effect on breast cell proliferation and therefore on breast cancer
risk, in line with results from in vitro studies (Maggiolini et al,
1999).
Since adipose women have a higher conversion from androgens
into oestrogens in the adipose tissue, it has been hypothesised that
BMI might actually be in the aetiological pathway, rather than act
as a confounder. This may be the case for the reproductive risk
factors as well (Bernstein and Ross, 1993). Adjustment for these
risk factors would then lead to overcorrection of the results. In line
Table 6 Risks of breast cancer for quartiles of hormone levels stratified for the time period between urine collection and diagnosis of breast cancer (o10
years; X10 years)
Time interval between urine collection and diagnosis of breast cancer
o10 years X10 years
Women in
subcohort
(n=382)
Breast cancer
cases
(n=184) IRR
a 95% CI
Breast cancer
cases
(n=180) IRR
a 95% CI
Oestrone
0.06–1.19ngmg
 1 95 31 1.0 F 26 1.0 F
1.19–1.77ngmg
 1 95 40 1.5 0.8–2.7 55 2.2 1.3–4.0
1.78–2.50ngmg
 1 95 43 1.2 0.7–2.2 36 1.2 0.7–2.2
42.50ngmg
 1 95 69 2.6 1.5–4.6 63 2.3 1.3–4.0
Ptrend 0.002 0.04
Oestradiol
0.08–0.34ngmg
 1 95 38 1.0 F 39 1.0 F
0.34–0.49ngmg
 1 96 34 0.9 0.5–1.6 45 1.3 0.7–2.2
0.49–0.77ngmg
 1 96 55 1.4 0.8–2.4 46 1.3 0.8–2.3
40.77ngmg
 1 95 57 1.9 1.1–3.3 50 1.2 0.7–2.1
Ptrend 0.007 0.45
Testosterone
0.03–1.85ngmg
 1 95 39 1.0 F 41 1.0 F
1.86–2.71ngmg
 1 96 51 1.2 0.7–2.2 37 1.0 0.6–1.7
2.72–4.16ngmg
 1 96 55 1.4 0.8–2.5 57 1.5 0.9–2.6
44.16ngmg
 1 95 40 2.1 1.2–3.5 45 1.2 0.7–2.1
Ptrend 0.009 0.24
5a-androstane-3a,1 7 b-diol
0.85–15.93ngmg
 1 97 29 1.0 F 33 1.0 F
15.94–23.67ngmg
 1 94 52 1.8 1.0–3.2 51 1.6 0.9–2.8
23.68–33.65ngmg
 1 96 46 1.6 0.9–2.9 55 1.8 1.0–3.0
433.65ngmg
 1 95 57 2.3 1.3–4.1 40 1.3 0.8–2.4
Ptrend 0.01 0.26
aAdjusted for family history of breast cancer (yes/no). IRR, incidence rate ratio.
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factors altered the risks found for any of the hormones. ‘Family
history of breast cancer’ was the only confounder in our study; it
was more prevalent among breast cancer cases, and women with a
positive family history showed higher levels of (especially)
oestrone and testosterone (statistically nonsignificant). Excluding
women with such a positive family history from the analyses did
not change the results (data not shown).
In conclusion, this study, the largest prospective study on
endogenous hormones and breast cancer risk so far, shows that
women with higher levels of oestrogens and androgens after
menopause have an increased risk for breast cancer compared to
women with lower concentrations.
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